共 181 条
- [91] Versluys B(2000)Evaluation of the clinical utility of cerebrospinal fluid (CSF) indices of inflammatory markers in multiple sclerosis Acta Neurol Scand 101 239-1566
- [92] Lannoy D(2015)Characterization of CD30/CD30L(+) cells in peripheral blood and synovial fluid of patients with rheumatoid arthritis J Immunol Res 2015 729654-2196
- [93] Richardson PG(2016)Requirement of CD30 expression on CD4 T cells in the pathogenesis of experimental autoimmune encephalomyelitis J Neuroimmunol 291 39-1862
- [94] Jawad M(2001)Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases Trends Immunol 22 72-1356
- [95] Rosen DB(2010)Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N Engl J Med 363 1812-1377
- [96] Lapusan S(2012)Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma J Clin Oncol 30 2183-344
- [97] Kung Sutherland MS(2016)Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma Blood 128 1562-266
- [98] Stein EM(2012)Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study J Clin Oncol 30 2190-3100
- [99] Stein H(2015)Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 385 1853-77
- [100] Durkop H(2013)Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study Lancet Oncol 14 1348-3758